UNSPSC 51171941: Metiamide

This classification denotes a histamine-2 receptor antagonist with the molecular formula C9H16N4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3K7670861M, chemically known as urea, 1-methyl-3-(2-(((5-methylimidazol-4-yl)methyl)thio)ethyl)-2-thio- but generally known as metiamide, which bears US NIH Compound Identifier 1548992. European Medicines Agency schedules Metiamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08881MIG. The term METIAMIDE is an International Non-Proprietary Name.

UNSPSC 51171941 Metiamide (Commodity) covers pharmaceutical substances used in drug testing and screening applications, as evidenced by recent state and local procurement activity centered on immunoassay testing materials and confirmation reagents. State and local governments buy metiamide and related testing compounds primarily as components within offender drug screening programs, correctional supervision initiatives, and broader pharmacy benefit programs. The buying bodies span county corrections departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions and supporting wholesalers. Testing volumes under current contracts are substantial—the Collin County solicitation alone encompasses approximately 25,031 annual tests across five-panel and six-panel screening methodologies with LC/MS/MS or GC/MS confirmation protocols.

Recent activity centers on Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with a response deadline of July 23, 2026 and an estimated contract value of $600,000 over two years with three optional one-year renewals; the county requires vendors to maintain lab certification from SAMHSA, TX DPS, or CAP and to provide screening with automatic confirmation of positives under a per-test pricing model. The Texas Health and Human Services Commission issued exploratory RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling broader state interest in pharmacy supply chain optimization. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to be distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with all products required to comply with cGMP and DSCSA regulations and available by May 15, 2026 for an effective date of July 1, 2026. The contract term under MMCAP is two years with optional extensions at the alliance's discretion.